Amgen Has Raised Its 2026 Outlook Twice, and $1,000 From Five Years Ago Is Now Worth More Than $2,500
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Amgen (NASDAQ:AMGN | AMGN Price Prediction) has spent five years replacing aging blockbusters with a newer growth portfolio, and 2026 is the year that shift showed up in the numbers. Management raised its full-year outlook in August and again in November, and the stock is up 44.13% year to date.
Out With Prolia, In With Repatha and IMDELLTRA
Amgen’s legacy franchises are shrinking fast. In the third quarter, Prolia fell 45%, and XGEVA dropped 47% as biosimilars launched globally. Medicare Part D price setting under the Inflation Reduction Act also cut Enbrel’s net selling price by 14%. The Horizon Therapeutics acquisition, which closed in 2023, brought in rare-disease drugs like UPLIZNA and TEPEZZA, plus debt that remains at $54.0 billion.
The newer drugs are now making up the difference. Third-quarter revenue reached $10.365 billion, up 8.45%. Repatha brought in $1.085 billion (+37%), UPLIZNA grew 191%, and IMDELLTRA rose 128%. Non-GAAP EPS of $6.45 exceeded the $5.7822 consensus, the sixth consecutive beat.
February’s starting guidance called for revenue of $37.0 billion to $38.4 billion[1] and non-GAAP EPS of $21.60 to $23.00. After six key growth drivers rose 26%[2] in the second quarter, Amgen lifted that to $38.2 billion to $39.4 billion and $22.30 to $23.50. November’s raise moved it to $38.9 billion to $39.7 billion and $22.90 to $23.70.
Your $1,000 Became $2,603 and Beat the Market Everywhere
Amgen returns include reinvested dividends, while the SPY benchmark reflects price changes only. Including SPY’s dividends would narrow Amgen’s reported lead. The S&P 500 benchmark uses the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) price change.
1-Year Return
- Initial Investment: $1,000
- Current Value: $1,411
- Total Return: 41.08%
- S&P 500 (same period): $1,101 (10.12%)
5-Year Return
- Initial Investment: $1,000
- Current Value: $2,603
- Total Return: 160.26%
- Annualized Return: 21.08%
- S&P 500 (same period): $1,581 (58.06%)
10-Year Return
- Initial Investment: $1,000
- Current Value: $4,258
- Total Return: 325.81%
- Annualized Return: 15.59%
- S&P 500 (same period): $3,387 (238.65%)
Timing counted, as shares sat at $338.01[3] when first-quarter results landed in April, then reached $466.36 by the November report. Holders needed patience while biosimilars ate into Prolia before the newer drugs took over.
A 20x Earnings Multiple and a MariTide Catalyst Shape the Outlook
Investors are betting that Repatha, IMDELLTRA and UPLIZNA keep outpacing biosimilar erosion and that MariTide, a monthly obesity candidate in Phase 3, reaches market. At its November 13 closing price of $465.67, Amgen trades at roughly 20 times the midpoint of its 2026 adjusted EPS guidance. Management also stated, “we do not anticipate a step-down in operating margin” in 2027.
Skeptics worry that MariTide could stumble against established GLP-1 rivals, since the obesity program carries much of the long-term premium. The FDA’s request to withdraw TAVNEOS and the heavy debt load add pressure. On balance, a diversified portfolio is overcoming its decline at a reasonable multiple.
Contact [email protected] for any questions or corrections.







